Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Urogen Pharma Ltd (URGN)

Urogen Pharma Ltd (URGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Urogen Pharma Ltd 400 Alexander Park Drive Princeton NJ 08540 USA

www.urogen.com Employees: 201 P: 646-768-9780

Description:

UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel.

Key Statistics

Overview:

Market Capitalization, $K 305,371
Enterprise Value, $K 308,101
Shares Outstanding, K 23,454
Annual Sales, $ 82,710 K
Annual Net Income, $ -102,240 K
Last Quarter Sales, $ 21,850 K
Last Quarter Net Income, $ -33,400 K
EBIT, $ -79,690 K
EBITDA, $ -79,920 K
60-Month Beta 1.11
% of Insider Shareholders 5.10%
% of Institutional Shareholders 91.29%
Float, K 22,258
% Float 94.90%
Short Volume Ratio 0.49

Growth:

1-Year Return 12.79%
3-Year Return -28.50%
5-Year Return -44.74%
5-Year Revenue Growth 7,219.47%
5-Year Earnings Growth 26.04%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.91 on 08/13/24
Next Earnings Date 11/06/24 [BMO]
Earnings Per Share ttm -3.28
EPS Growth vs. Prev Qtr 6.19%
EPS Growth vs. Prev Year 11.65%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

URGN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -53.18%
Profit Margin % -123.61%
Debt/Equity 3.23
Price/Sales 3.47
Price/Cash Flow N/A
Price/Book 9.48
Book Value/Share 1.29
Interest Coverage -5.68
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar